There were 22 pharmaceutical acquisitions in the second quarter of 2020, slightly below the average of 27.
The biggest deal so far has been Gilead’s acquisition of Forty Seven for $4.9 billion, significantly lower than the average largest deal, according to EvaluatePharma.
The five largest pharmaceuticals M&A deals this year:
- Gilead’s acquisition of Forty Seven — $4.9 billion
- Novo Nordisk’s acquisition of Corvidia — $2.1 billion
- Alexion’s acquisition of Portola — $1.4 billion
- Eli Lilly’s acquisition of Dermira — $1.1 billion
- Takeda’s divestiture of select drugs to Hypera Pharma — $825 million
More articles on pharmacy:
US sues Teva for alleged MS drug kickback scheme
J&J to acquire Momenta Pharma for $6.5B
White House adviser says Kodak execs made ‘dumbest decisions’ on government loan
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
